The effects of patient function and dependence on costs of care in Alzheimer's disease

Geriatric Research, Education, and Clinical Center, Program of Research on Serious Physical and Mental Illness, James J Peters Veterans Affairs Medical Center, Bronx, New York 10468, USA.
Journal of the American Geriatrics Society (Impact Factor: 4.22). 08/2008; 56(8):1497-503. DOI: 10.1111/j.1532-5415.2008.01798.x
Source: PubMed

ABSTRACT To estimate incremental effects of patients' dependence and function on costs of care during the early stages of Alzheimer's disease (AD) and to compare strengths of their relationships with different cost components.
Multicenter, cross-sectional, observational study.
Three university hospitals in the United States.
One hundred seventy-nine community-living patients with probable AD, with modified Mini-Mental State Examination scores of 30 or higher.
Patients' dependence was measured using the Dependence Scale (DS). Functional capacity was measured using the Blessed Dementia Rating Scale (BDRS). Total cost was measured by summing direct medical costs and informal costs. Direct medical costs included costs of hospitalization, outpatient treatment and procedures, assistive devices, and medications. Informal costs were estimated from time spent helping with basic and instrumental activities of daily living for up to three caregivers per patient using national average hourly earnings as wage rate.
DS and BDRS were associated with higher total cost; a 1-point increase in DS was associated with a $1,832 increase in total cost, and a 1-point increase in BDRS was associated with a $3,333 increase. Examining component costs separately identified potential differences between DS and BDRS. A 1-point increase in BDRS was associated with a $1,406 increase in direct medical cost. A 1-point increase in DS was associated with a $1,690 increase in informal cost.
Patients' dependence and function related differently to direct medical and informal cost, suggesting that measures of function and dependence provided unique information for explaining variations in cost of care for patients with AD, highlighting the value in measuring both constructs.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: This study was performed to assess the economic effect of interventions affecting transitions between dementia care settings in Germany. Methods: A Markov-model that models the course of dementia with respect to typical care setting transitions was derived. Model data and parameters were retrieved by literature reviews. A deterministic and probabilistic sensitivity analysis was conducted to account for parameter uncertainty. Results: In the base case, the expected present value of remaining lifetime costs is 25,326 for each cohort member. As a function of effectiveness, pharmaceutical interventions may reduce the costs by 2% to 13% and psychosocial interventions come with savings of 1% to 10%. A structural intervention-promoting group living as a substitute for nursing home care increases costs by 2% to 8%. Sensitivity analyses indicate high variance and variability of results, as well as valuation of informal care being a crucial parameter. Conclusions: There are economic benefits of delayed tansitions to institutional settings, especially from the viewpoint of statutory care insurances, but these do unlikely exceed intervention costs. Thus, further intervention effects should be considered. Ultimately, concentrating research on preventive and protective factors of dementia could lead to an efficient intervention from every perspective.
    Value in Health 09/2014; 17(6):679-85. DOI:10.1016/j.jval.2014.06.008 · 2.89 Impact Factor
  • Source
    01/2014; 04(03). DOI:10.4172/2161-0460.1000e132
  • [Show abstract] [Hide abstract]
    ABSTRACT: Considerable advances have been made in modeling Alzheimer's disease (AD), with a move towards individual-level rather than cohort models and simulations that consider multiple dimensions when evaluating disease severity. However, the possibility that disease-modifying agents (DMAs) may emerge requires an update of existing modeling frameworks.
    PharmacoEconomics 08/2014; 32(11). DOI:10.1007/s40273-014-0203-5 · 3.34 Impact Factor

Full-text (2 Sources)

Available from
May 17, 2014